These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 29739368)
1. Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer. Sato H; Narita S; Tsuchiya N; Koizumi A; Nara T; Kanda S; Numakura K; Tsuruta H; Maeno A; Saito M; Inoue T; Satoh S; Nomura K; Habuchi T BMC Urol; 2018 May; 18(1):32. PubMed ID: 29739368 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer. Narita S; Nomura K; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nagashima K; Habuchi T Sci Rep; 2019 Aug; 9(1):12071. PubMed ID: 31427687 [TBL] [Abstract][Full Text] [Related]
3. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality. Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757 [TBL] [Abstract][Full Text] [Related]
4. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Parikh M; Tangen C; Hussain MHA; Gupta S; Callis S; Jo Y; Harzstark A; Paller CJ; George S; Zibelman MR; Cheng HH; Maughan BL; Zhang J; Pachynski RK; Bryce AH; Lin DW; Quinn DI; Lerner SP; Thompson IM; Dorff TB; Lara PN; Agarwal N Eur Urol Oncol; 2024 Oct; 7(5):1097-1104. PubMed ID: 38523017 [TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer. Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252 [TBL] [Abstract][Full Text] [Related]
6. Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis. Rossignol T; Gourtaud G; Senechal C; Sadreux Y; Roux V; Blanchet P; Brureau L Prostate; 2021 Oct; 81(14):1091-1096. PubMed ID: 34320690 [TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900 [TBL] [Abstract][Full Text] [Related]
8. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir. Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426 [TBL] [Abstract][Full Text] [Related]
10. Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer. Nakanishi S; Goya M; Tamaki M; Oshiro T; Saito S BMC Res Notes; 2021 Jun; 14(1):227. PubMed ID: 34082809 [TBL] [Abstract][Full Text] [Related]
11. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? Perachino M; Cavalli V; Bravi F BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358 [TBL] [Abstract][Full Text] [Related]
12. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes. Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323 [TBL] [Abstract][Full Text] [Related]
14. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy. Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738 [TBL] [Abstract][Full Text] [Related]
15. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. Yu EY; Li H; Higano CS; Agarwal N; Pal SK; Alva A; Heath EI; Lam ET; Gupta S; Lilly MB; Inoue Y; Chi KN; Vogelzang NJ; Quinn DI; Cheng HH; Plymate SR; Hussain M; Tangen CM; Thompson IM J Clin Oncol; 2015 May; 33(14):1601-8. PubMed ID: 25847934 [TBL] [Abstract][Full Text] [Related]
16. Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy. López-Torrecilla J; Boladeras A; Cabeza MA; Zapatero A; Jove J; Esteban LM; Henriquez I; Casaña M; González-San Segundo C; Gómez-Caamaño A; Mengual JL; Hervás A; Muñoz JL; Sanz G Strahlenther Onkol; 2015 Oct; 191(10):792-800. PubMed ID: 26156249 [TBL] [Abstract][Full Text] [Related]
17. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106 [TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272 [TBL] [Abstract][Full Text] [Related]
19. Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer. Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Orsola A; Planas J; Catalán R; Reventós J Int J Biol Markers; 2005; 20(4):209-16. PubMed ID: 16398402 [TBL] [Abstract][Full Text] [Related]
20. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy. Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]